PHARMACEUTICAL 2017

EnzymeBioSystems
Rank 89 of 308



PHARMACEUTICAL 2017

EnzymeBioSystems
Rank 89 of 308

The relative strengths and weaknesses of EnzymeBioSystems are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of EnzymeBioSystems compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 148% points.The greatest weakness of EnzymeBioSystems is the variable Other Expenses, reducing the Economic Capital Ratio by 94% points.

The company's Economic Capital Ratio, given in the ranking table, is 327%, being 82% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	140
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	0.10
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	114
Other Liabilities	4.0
Other Net Income	0
Other Revenues	0
Property and Equipment	0
Research and Development	11
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	140
Liabilities	4.1
Expenses	125
Revenues	0
Stockholders Equity	136
Net Income	-125
Comprehensive Net Income	-125
BaseVar	135
ECR before LimitedLiability	237%
Economic Capital Ratio	327%